This study is currently not recruiting participants.

A Phase 2 Multicenter International Randomized Double Blind Placebo-Controlled Study of Gemcitabine Combined with PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Compared to Gemcitabine Combined with Placebo in Patients with Stage IV Previously Un

Study of Investigational Medication with Chemotherapy for Pancreatic Cancer

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

The purpose of this study is to determine how well the dose of PEGPH20 works with gemcitabine for the treatment of pancreatic cancer.

Detailed description of study

The purpose of this study is to determine how well the dose of PEGPH20 works with gemcitabine for the treatment of pancreatic cancer.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Pancreatic Cancer
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the effects of an investigational medication when used with a chemotherapy drug for treating pancreatic cancer. Pancreatic cancer is a disease where cancer cells form in the tissues of the pancreas, an organ that helps with digestion and blood sugar regulation.

Participants in this study will receive either the investigational medication along with the chemotherapy drug or a placebo, which is an inactive substance that looks like the investigational medication but does not contain any medicine.

  • Who can participate: Adults aged 18 and older diagnosed with pancreatic cancer and meeting specific health criteria are eligible to participate.
  • Study details: Participants will be randomly assigned to receive either the investigational medication with chemotherapy or a placebo.
Updated on 19 Feb 2024. Study ID: 1205008697

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team